Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-831 in Healthy Subjects
NCT03224325Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Jul 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of luvadaxistat in schizophrenia and Friedreich's ataxia (FA) (7 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event up to 48 days, Percentage of Participants Who Met the Markedly Abnormal Criteria for Safety Laboratory Tests up to 48 days and 2 more. Started Jul 2017; status: completed.
02
Drugs
luvadaxistat
03
Conditions
schizophreniaFriedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT03224325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224325.